March 2025 Volume 21, Issue 1

Volume 21, Issue 1 | March 2025
March 2025
In this Issue
Women's Health

Rebuilding vaginal health with beneficial bacteria
Bacteria from healthy vaginas show promise in protecting women from pathogens, but advancing their development requires more funding and research.
A new migraine medication is on the horizon
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
A new drug-device combination for non-hormonal contraception
Sabrina Johnson at Daré Bioscience is redefining contraception with Ovaprene, a non-hormonal, monthly option for safe and effective birth control.Metabolic Disease

Finding new strategies to treat Pompe disease
Enzyme replacement therapy has been the mainstay of Pompe disease. New and emerging therapies may provide more options for patients.
Illuminating the full side effect profile of GLP-1 drugs
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.Microbiology

Diagnostics for faster antimicrobial susceptibility testing
New phenotypic methods can help identify the best antibiotic to treat sepsis, UTIs, and other bacterial infections.Editors Insight

Editorial: Of snakes and science communication
A close encounter with a venomous critter sparked insight for communicating science in times of stress.Cancer

Targeting aneuploidy to treat cancer
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe